Clarivate Closes $488.4M LS&H Sale as Organic Growth Hits 0.4%
LONDON – November 03, 2026 -- Clarivate Plc (NYSE: CLVT) closed the sale of its Life Sciences & Healthcare (LS&H) segment on October 6, 2026 for net cash proceeds of $488.4 million, and reported third-quarter organic revenue growth of 0.4% for continuing operations alongside a $80.8 million net loss driven by a goodwill impairment.
Organic ACV rises 1.8% as subscriptions replace transactional sales
Organic annual contract value (ACV) for continuing operations grew 1.8% against September 30, 2025. Organic subscription revenue increased 1.5%, helped by new sales and pricing actions, while organic re-occurring revenue rose 0.7% on higher IP volumes. Organic recurring revenue, the combination of both, grew 1.3%, or $5.7 million.